In this report, Argaam highlights the expected results of Jamjoom Pharmaceuticals Factory Co. in Q4 2024, as well as its key events, quarterly sales and profit, and performance indicators.
The company is projected to post a 22% year-on-year (YoY) jump in the fourth-quarter revenue to SAR 253.75 million.
| Item | Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 (Average Estimate) |
|---|---|---|---|---|---|
| Sales | 207.86 | 385.46 | 345.74 | 327.58 | 253.75 |
| Change % | 5.60% | 28.12% | 15.86% | 11.95% | 22.08% |
| Income from Affiliate | 5.33 | 1.76 | 2.01 | 7.07 | NA |
| Change % | NA | NA | NA | NA | NA |
| Item | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 (Average Estimate) |
|---|---|---|---|---|---|
| Net Income | 44.48 | 102.97 | 106.95 | 94.99 | 55.80 |
| Extraordinary income/expense | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Net Profit Before Unusual Items | 44.48 | 102.97 | 106.95 | 94.99 | - |
| EPS Before Unusual Items (Riyal/Share) | 0.64 | 1.47 | 1.53 | 1.36 | 0.80 |
Key events in Q4 2024
The company's key performance indicators remained steady, standing on par with the results of the first nine months of 2024 and projections for the remainder of the year.
Average forecasts
The company is forecast to record a net profit of SAR 55.8 million in Q4 2024, a rise of 25.4% from SAR 44.5 million in Q4 2023, based on average estimates by five research houses.
| Analyst | Million Riyals |
|---|---|
| United Securities Company | 69.00 |
| GIB Capital LLC | 57.00 |
| Osool and Bakheet Investment Co. | 55.21 |
| SNB Capital Company | 49.80 |
| Al Rajhi Capital Company | 48.00 |
| Average | 55.80 |
| Net Profit Before Unusual Items (2023 - Q4) | 44.48 |
| Change % | 25.44% |
Performance & profitability indicators
The following table shows the stock performance trailing 12 months (TTM) and year to date, as well as its P/E and earnings per share:
| Item | The Company | TASI |
|---|---|---|
| YTD | 7.36 % | 2.80 % |
| Change(12M) | 17.72 % | 3.58 % |
| Previous Close | 165.00 | 12,439.48 |
| P/E adjusted (x) | 32.74 | 25.07 |
| EPS (TTM) before unusual items (SAR/Share) | 4.99 | - |
| P/E (TTM) | 32.74 |
| P/E Before Unusual Items (TTM) | 32.74 |
| P/BV | 7.92 |
| Dividend Yield | 2.17 % |
| Market Cap. (M) | 11,438.00 |
| Return on Average Assets | 19.87 % |
| Return on Average Equity | 24.90 % |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}